The new drug, Setmelanotide, is an eight-amino acid cyclic peptide labeled as BIM-22493 or RM-493 that functions as an MC4R agonist to treat the monogenic causes of obesity caused by POMC deficiency by lowering food intake and restoring insulin sensitivity [67,68]. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.